NCT04910685 2026-04-06
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
Phase 2/3 Recruiting
Clinical Trials
11 trialsNCT03401060 2026-03-31
DenosuMast
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT05186753 2026-03-04
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cogent Biosciences, Inc.
Phase 2 Active not recruiting
NCT06748001 2026-02-09
Avapritinib Rollover Study
Blueprint Medicines Corporation
Phase 4 Recruiting
NCT04681105 2026-01-28
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
City of Hope Medical Center
Phase 1 Completed
NCT05362773 2026-01-13
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MacroGenics
Phase 1 Recruiting
NCT03731260 2025-09-23
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
Phase 2 Active not recruiting
NCT00769587 2025-09-22
Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis
Centre Hospitalier Universitaire, Amiens
Completed
NCT04996875 2025-05-30
APEX
Cogent Biosciences, Inc.
Phase 2 Recruiting
NCT00449748 2025-05-01
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03580655 2025-04-30
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Blueprint Medicines Corporation
Phase 2 Completed